LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
38 funds hold it · Insiders net selling
Net selling: insiders sold $28.6M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 2, 2026
Financial period
Q3 2026
Earnings per share
$3.71 expected
Revenue
$1.19B expected
FY 2026 guidance
$4.74B to $4.77B
No comparable estimate
Estimates as of Nov 8, 2026
EPS expected
$3.37 to $3.91
Revenue expected
8 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 2, 2026 | $4.01est. $3.71 | +7.98%beat | $1.21Best. $1.19B+1.83% | +9.9%from $1.11B |
| Jun 30, 2026Reported Aug 4, 2026 | $4.27est. $3.93 | +8.54%beat | $1.22BSEC filing | +9.7%from $1.11B |
| Mar 31, 2026Reported May 5, 2026 | $3.47est. $3.41 | +1.74%beat | $1.14BSEC filing | +14.3%from $998.4M |
| Dec 31, 2025Reported Feb 2, 2026 | $3.08est. $2.94 | +4.81%beat | $1.09BAlpha Vantage | +14.3%from $954.3M |
| Sep 30, 2025Reported Nov 3, 2025 | $3.40est. $3.15 | +7.94%beat | $1.11BSEC filing | +13.3%from $975.5M |
| Jun 30, 2025Reported Aug 4, 2025 | $3.63est. $3.30 | +10.00%beat | $1.11BSEC filing | +10.6%from $1.00B |
| Mar 31, 2025Reported May 1, 2025 | $2.96est. $2.84 | +4.23%beat | $998.4MSEC filing | +3.6%from $964.1M |
| Dec 31, 2024Reported Feb 3, 2025 | $2.62est. $2.40 | +9.17%beat | $954.3MAlpha Vantage | +5.8%from $901.6M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.09B | $1.14B | $1.22B | $1.21B |
| Cost of what it sold | $432.5M | $418.1M | $437.5M | $449.9M |
| Gross profit | $658.1M | $722.7M | $779.1M | $764.3M |
| What it spent | ||||
| Research and development | $66.8M | $65.8M | $65.4M | $68.8M |
| Sales and admin | $108.6M | $119.1M | $116.8M | $123.3M |
| Other operating costs | $167.1M | $175.3M | $171.3M | $169.8M |
| Total operating expenses | $342.5M | $360.2M | $353.5M | $361.9M |
| What was left | ||||
| Operating profit | $315.6M | $362.6M | $425.6M | $402.3M |
| Interest on debt | $10.5M | $7.7M | $10.2M | $7.5M |
| Profit before tax | $307.0M | $355.4M | $417.2M | $399.3M |
| Tax | $58.8M | $77.0M | $78.8M | $82.2M |
| Net profit | $248.2M | $278.4M | $338.4M | $317.1M |
| EBITDA | $356.2M | $400.9M | $468.5M | $447.3M |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
30 Newly Overvalued Stocks This Week
BearishNov 9Should You Continue to Hold TMO Stock in Your Portfolio?
Leans bullishNov 9Notable healthcare headlines for the week: Moderna, Pfizer, and CVS Health in focus
BullishNov 8Executive VP and GM Global Reference Laboratories Michael Lane Sold A Bunch Of Shares In IDEXX Laboratories
Leans bearishNov 8Align Technology, Inc. (ALGN) stock price, news, quote and history
NeutralNov 8IDEXX Laboratories, Inc. (IDXX) stock price, news, quote and history
NeutralNov 7IDEXX Laboratories, Inc. (IDXX) Stock Price, News, Quote & History
NeutralNov 7IDEXX Laboratories, Inc. (IDXX) Seasonal Returns Chart
NeutralNov 6
